In addition, there are other potentially targeted low-frequency mutations in ICC, such as BRAF V600E mutation, HER2 amplification and NTRK fusion, etc. Although clinical trials are difficult to conduct due to low incidence, basket trials have confirmed the therapeutic value of these targets in ICC [81]. This evidence concerns the gene BRAF and intrahepatic cholangiocarcinoma.